Market Summary
USD88.06+1.02
Market Closed1.17%
BMRN Alerts
BMRN Stock Price
BMRN RSI Chart
BMRN Valuation
BMRN Price/Sales (Trailing)
BMRN Profitability
BMRN Fundamentals
BMRN Revenue
BMRN Earnings
Price Action
52 Week Range
80.53117.77
(Low)(High)
Last 7 days
-0.9%
Last 30 days
-6.0%
Last 90 days
-4.5%
Trailing 12 Months
7.2%
BMRN Financial Health
BMRN Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for BMRN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-16 | Ajer Jeffrey Robert | sold | -450,000 | 90.00 | -5,000 | evp, chief commercial officer |
2023-08-10 | FUCHS HENRY J | sold | -1,085,110 | 90.4259 | -12,000 | president, worldwide r&d |
2023-08-09 | Guyer Charles Greg | sold | -500,109 | 93.304 | -5,360 | evp, chief technical officer |
2023-08-08 | BIENAIME JEAN JACQUES | sold | -529,740 | 88.29 | -6,000 | chief executive officer |
2023-08-08 | Davis George Eric | sold | -983,662 | 89.4238 | -11,000 | evp, chief legal officer |
2023-08-07 | BIENAIME JEAN JACQUES | sold | -352,400 | 88.1 | -4,000 | chief executive officer |
2023-06-29 | Mueller Brian | sold (taxes) | -869,735 | 88.93 | -9,780 | evp, chief financial officer |
2023-05-23 | Dere Willard H | acquired | - | - | 4,190 | - |
2023-05-23 | MEIER RICHARD A | acquired | - | - | 4,190 | - |
2023-05-23 | Slamon Dennis | acquired | - | - | 4,190 | - |
Which funds bought or sold BMRN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Baystate Wealth Management LLC | reduced | -25.00 | -12,892 | 26,004 | -% |
2023-09-21 | Jefferies Group LLC | added | 794 | 1,644,580 | 1,846,290 | 0.01% |
2023-09-20 | BARCLAYS PLC | added | 65.83 | 74,627,000 | 230,678,000 | 0.15% |
2023-09-18 | WASHINGTON CAPITAL MANAGEMENT, INC | unchanged | - | -68,640 | 563,420 | 0.48% |
2023-09-12 | Farther Finance Advisors, LLC | added | 309 | 2,831 | 3,901 | -% |
2023-08-29 | EFG Asset Management (Americas) Corp. | new | - | 1,439,060 | 1,439,060 | 0.33% |
2023-08-28 | DT Investment Partners, LLC | unchanged | - | -1,844 | 20,559 | -% |
2023-08-24 | PERCEPTIVE ADVISORS LLC | reduced | -60.89 | -42,633,600 | 22,814,800 | 0.66% |
2023-08-24 | Alberta Investment Management Corp | added | 50.57 | 123,106 | 482,894 | -% |
2023-08-24 | Arlington Capital Management, Inc. | sold off | -100 | -2,801,480 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
BMRN Alerts
Schedule 13G FIlings of Biomarin Pharmaceutical
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | dodge & cox | 7.7% | 14,383,663 | SC 13G/A | |
| Feb 13, 2023 | capital research global investors | 3.0% | 5,651,001 | SC 13G/A | |
| Feb 09, 2023 | primecap management co/ca/ | 9.46% | 17,580,859 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.34% | 17,365,080 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 8.2% | 15,206,690 | SC 13G/A | |
| Mar 11, 2022 | blackrock inc. | 7.6% | 14,021,292 | SC 13G/A | |
| Feb 14, 2022 | dodge & cox | 8.1% | 14,825,049 | SC 13G/A | |
| Feb 10, 2022 | primecap management co/ca/ | 9.7% | 17,804,780 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 8.91% | 16,351,031 | SC 13G/A | |
| Feb 08, 2022 | blackrock inc. | 7.6% | 14,021,292 | SC 13G |
Recent SEC filings of Biomarin Pharmaceutical
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 17, 2023 | 4 | Insider Trading | |
| Aug 16, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 11, 2023 | 4 | Insider Trading | |
| Aug 10, 2023 | 4 | Insider Trading | |
| Aug 10, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 09, 2023 | 4 | Insider Trading | |
| Aug 09, 2023 | 4 | Insider Trading | |
| Aug 09, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 08, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 08, 2023 | 144 | Notice of Insider Sale Intent |
Peers (Alternatives to Biomarin Pharmaceutical)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 143.9B | 26.6B | 4.94% | 20.46% | 18.04 | 5.41 | 0.75% | 21.34% |
GILD | 94.2B | 27.4B | -1.73% | 23.33% | 17.17 | 3.44 | -0.48% | 32.56% |
MRNA | 37.4B | 10.7B | -12.34% | -18.02% | 30.97 | 3.51 | -53.67% | -91.41% |
BIIB | 37.3B | 10.0B | -2.41% | 31.83% | 14.01 | 3.74 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.2B | 1.7B | 6.64% | 14.01% | 63.44 | 6.69 | 29.01% | 1345.90% |
BBIO | 4.3B | - | -10.44% | 191.13% | -7.34 | 48.33 | 54.84% | -12.96% |
DNLI | 2.9B | - | -7.08% | -17.64% | -22.89 | 37.44 | 122.90% | 54.78% |
BEAM | 1.8B | 80.2M | 1.68% | -49.31% | -5.62 | 22.95 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.4B | 121.2M | -15.01% | -21.70% | -4.98 | 11.8 | -70.36% | -531.73% |
REPL | 941.3M | 15.3M | -22.34% | -0.87% | -5.18 | 61.48 | 1090.59% | -36.57% |
NVAX | 670.5M | 1.6B | -11.68% | -62.32% | -1.14 | 0.42 | 23.74% | 60.24% |
FATE | 199.0M | - | -23.19% | -90.40% | -0.94 | 1.45 | 116.83% | 16.61% |
SGMO | 118.0M | - | -12.12% | -85.84% | -0.59 | 0.49 | 113.96% | -15.19% |
VXRT | 107.9M | 2.1M | -9.82% | -66.03% | -1.07 | 52.51 | 487.70% | -8.66% |
IBIO | 3.7M | - | -11.16% | -96.28% | -0.05 | 3.21 | - | -129.46% |
Biomarin Pharmaceutical News
Returns for BMRN
Cumulative Returns on BMRN
1.7%
10-Year Cumulative Returns
-1.4%
7-Year Cumulative Returns
-2.1%
5-Year Cumulative Returns
4.4%
3-Year Cumulative Returns
Risks for BMRN
What is the probability of a big loss on BMRN?
65.4%
Probability that Biomarin Pharmaceutical stock will be more than 20% underwater in next one year
30%
Probability that Biomarin Pharmaceutical stock will be more than 30% underwater in next one year.
18.5%
Probability that Biomarin Pharmaceutical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BMRN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Biomarin Pharmaceutical was unfortunately bought at previous high price.
Drawdowns
Financials for Biomarin Pharmaceutical
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 2.8% | 2,235 | 2,173 | 2,096 | 2,008 | 1,912 | 1,880 | 1,846 | 1,849 | 1,917 | 1,844 | 1,860 | 1,863 | 1,847 | 1,805 | 1,704 | 1,603 | 1,533 | 1,519 | 1,491 | 1,496 | 1,439 |
| Cost Of Revenue | 1.0% | 498 | 493 | 484 | 476 | 463 | 467 | 471 | 477 | 562 | 533 | 524 | 494 | 402 | 382 | 359 | 339 | 321 | 322 | 315 | 316 | 297 |
| Costs and Expenses | 2.0% | 2,143 | 2,102 | 1,946 | 1,900 | 1,854 | 1,850 | 1,929 | 1,917 | 1,987 | 1,968 | 1,904 | 1,864 | 1,788 | 1,747 | 1,805 | 1,732 | 1,683 | 1,652 | 1,615 | 1,524 | 1,464 |
| S&GA Expenses | 2.1% | 901 | 882 | 854 | 826 | 792 | 780 | 759 | 737 | 733 | 725 | 738 | 730 | 721 | 706 | 681 | 657 | 636 | 628 | 604 | 600 | 582 |
| R&D Expenses | 2.9% | 680 | 661 | 650 | 638 | 638 | 641 | 629 | 624 | 614 | 635 | 628 | 644 | 670 | 674 | 715 | 718 | 706 | 696 | 696 | 690 | 682 |
| EBITDA | -100.0% | - | 157 | 268 | 188 | 146 | 127 | 48.00 | 46.00 | 36.00 | 13.00 | 92.00 | 123 | 192 | 192 | 34.00 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.07* | 0.13* | 0.09* | 0.08* | 0.07* | 0.03* | 0.02* | 0.02* | 0.01* | 0.05* | 0.07* | 0.10* | 0.11* | 0.02* | - | - | - | - | - | - |
| Interest Expenses | -0.7% | 16.00 | 16.00 | 16.00 | 16.00 | 15.00 | 15.00 | 15.00 | 16.00 | 22.00 | 26.00 | 29.00 | 31.00 | 25.00 | 24.00 | 23.00 | 24.00 | 33.00 | 39.00 | 44.00 | 48.00 | 46.00 |
| Earnings Before Taxes | 49.8% | 108 | 72.00 | 150 | 101 | 56.00 | 36.00 | -75.35 | -55.64 | -70.69 | -127 | -49.00 | -11.92 | 59.00 | 59.00 | -94.81 | -128 | -157 | -144 | -142 | -44.80 | -46.00 |
| EBT Margin | -100.0% | - | 0.03* | 0.07* | 0.05* | 0.03* | 0.02* | -0.04* | -0.03* | -0.03* | -0.07* | -0.02* | -0.01* | 0.03* | 0.03* | -0.06* | - | - | - | - | - | - |
| Net Income | 39.6% | 100 | 72.00 | 142 | 84.00 | 54.00 | 39.00 | -64.08 | 11.00 | 832 | 790 | 854 | 852 | 122 | 114 | -23.85 | -42.52 | -110 | -89.53 | -77.21 | -124 | -124 |
| Net Income Margin | -100.0% | - | 0.03* | 0.07* | 0.04* | 0.03* | 0.02* | -0.03* | 0.01* | 0.44* | 0.43* | 0.46* | 0.46* | 0.07* | 0.06* | -0.01* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 31.00 | 55.00 | 66.00 | 16.00 | 47.00 | 209 | 182 | 173 | 115 | -28.95 | 22.00 | -10.34 | -68.89 | -96.76 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 2.0% | 6,563 | 6,434 | 6,375 | 6,264 | 6,146 | 6,063 | 6,005 | 5,977 | 5,898 | 5,805 | 5,848 | 6,158 | 5,302 | 4,723 | 4,690 | 4,558 | 4,393 | 4,435 | 4,427 | 4,695 | 4,625 |
| Current Assets | 3.8% | 2,950 | 2,842 | 2,751 | 2,683 | 2,518 | 2,394 | 2,274 | 2,312 | 2,358 | 2,289 | 2,342 | 2,739 | 2,648 | 2,116 | 1,942 | 1,859 | 1,807 | 1,917 | 2,056 | 2,408 | 2,280 |
| Cash Equivalents | 19.7% | 694 | 580 | 725 | 762 | 620 | 605 | 587 | 617 | 642 | 667 | 649 | 1,016 | 819 | 477 | 437 | 423 | 308 | 364 | 494 | 882 | 427 |
| Inventory | 6.2% | 976 | 919 | 894 | 839 | 802 | 786 | 777 | 749 | 711 | 714 | 699 | 701 | 744 | 706 | 680 | 609 | 579 | 535 | 531 | 508 | 473 |
| Net PPE | -0.1% | 1,067 | 1,068 | 1,073 | 1,052 | 1,049 | 1,040 | 1,035 | 1,025 | 1,027 | 1,022 | 1,032 | 1,015 | 1,011 | 1,010 | 1,011 | 969 | 963 | 952 | 949 | 924 | 900 |
| Goodwill | 0% | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 196 | 197 | 197 | 197 | 197 | 197 | 197 | 197 |
| Liabilities | 0.3% | 1,780 | 1,775 | 1,772 | 1,696 | 1,641 | 1,671 | 1,739 | 1,711 | 1,657 | 1,643 | 1,742 | 2,104 | 2,065 | 1,483 | 1,568 | 1,484 | 1,432 | 1,499 | 1,459 | 1,780 | 1,740 |
| Current Liabilities | -0.2% | 597 | 598 | 589 | 521 | 465 | 490 | 546 | 515 | 443 | 430 | 493 | 855 | 813 | 820 | 933 | 494 | 439 | 501 | 523 | 839 | 805 |
| Shareholder's Equity | 2.7% | 4,783 | 4,659 | 4,603 | 4,569 | 4,500 | 4,386 | 4,266 | 4,261 | 4,237 | 4,162 | 4,101 | 4,054 | 3,237 | 3,240 | 3,122 | 3,074 | 2,961 | 2,937 | 2,968 | 2,915 | 2,885 |
| Retained Earnings | 7.6% | -682 | -738 | -789 | -788 | -777 | -804 | -930 | -867 | -831 | -844 | -861 | -883 | -1,668 | -1,639 | -1,720 | -1,735 | -1,790 | -1,753 | -1,694 | -1,690 | -1,677 |
| Additional Paid-In Capital | 1.4% | 5,494 | 5,418 | 5,405 | 5,336 | 5,273 | 5,206 | 5,192 | 5,134 | 5,084 | 5,011 | 4,993 | 4,938 | 4,886 | 4,855 | 4,833 | 4,783 | 4,744 | 4,683 | 4,670 | 4,621 | 4,577 |
| Accumulated Depreciation | 2.8% | 829 | 807 | 802 | 782 | 762 | 741 | 721 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shares Outstanding | 0.3% | 188 | 188 | 186 | 186 | 185 | 184 | 184 | 183 | 183 | 182 | 182 | 181 | 181 | 180 | 180 | 179 | 179 | 178 | 178 | 177 | 177 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 9.4% | 161 | 147 | 176 | 180 | 119 | 146 | 305 | 280 | 269 | 214 | 85.00 | 156 | 140 | 88.00 | 48.00 | 40.00 | 17.00 | 8.00 | 20.00 | -14.55 | -23.46 |
| Share Based Compensation | 1.5% | 205 | 202 | 196 | 193 | 188 | 196 | 197 | 201 | 202 | 192 | 190 | 180 | 169 | 164 | 160 | 158 | 156 | 155 | 149 | 146 | 145 |
| Cashflow From Investing | 43.0% | -78.59 | -137 | -20.03 | -20.74 | -117 | -207 | -366 | -299 | -73.32 | -201 | -53.62 | -113 | -171 | 97.00 | -31.03 | -53.09 | 301 | 286 | 264 | 475 | -357 |
| Cashflow From Financing | 69.6% | -10.37 | -34.11 | -18.65 | -15.12 | -23.69 | -0.96 | -0.05 | -380 | -376 | 176 | 181 | 551 | 546 | -69.36 | -74.67 | -445 | -437 | -403 | -388 | -8.55 | 468 |
| Buy Backs | - | - | - | - | - | - | - | - | - | - | - | 50.00 | - | - | - | - | - | - | - | - | - | - |
BMRN Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| REVENUES: | ||||
| Total revenues | $ 595,275 | $ 533,798 | $ 1,191,690 | $ 1,053,157 |
| OPERATING EXPENSES: | ||||
| Cost of sales | 128,082 | 123,126 | 254,631 | 240,091 |
| Research and development | 177,363 | 158,190 | 349,209 | 319,026 |
| Selling, general and administrative | 215,336 | 196,835 | 438,339 | 391,454 |
| Intangible asset amortization and contingent consideration | 15,624 | 16,495 | 31,294 | 34,107 |
| Gain on sale of nonfinancial assets, net | 0 | 0 | 0 | (108,000) |
| Total operating expenses | 536,405 | 494,646 | 1,073,473 | 876,678 |
| INCOME FROM OPERATIONS | 58,870 | 39,152 | 118,217 | 176,479 |
| Interest income | 12,612 | 2,505 | 24,555 | 4,325 |
| Interest expense | (3,755) | (3,859) | (7,458) | (7,665) |
| Other income (expense), net | 3,083 | (2,947) | (7,747) | (4,101) |
| INCOME BEFORE INCOME TAXES | 70,810 | 34,851 | 127,567 | 169,038 |
| Provision for income taxes | 14,770 | 7,187 | 20,675 | 20,576 |
| NET INCOME | $ 56,040 | $ 27,664 | $ 106,892 | $ 148,462 |
| Earnings per share, basic (in dollars per share) | $ 0.30 | $ 0.15 | $ 0.57 | $ 0.80 |
| Earnings per share, diluted (in dollars per share) | $ 0.29 | $ 0.15 | $ 0.56 | $ 0.79 |
| Weighted average common shares outstanding, basic (in shares) | 187,948 | 185,254 | 187,311 | 184,710 |
| Weighted average common shares outstanding, diluted (in shares) | 194,998 | 187,448 | 194,756 | 191,096 |
| COMPREHENSIVE INCOME | $ 48,145 | $ 47,013 | $ 92,142 | $ 152,502 |
| Net product revenues | ||||
| REVENUES: | ||||
| Total revenues | 584,698 | 517,660 | 1,171,124 | 1,023,185 |
| Royalty and other revenues | ||||
| REVENUES: | ||||
| Total revenues | $ 10,577 | $ 16,138 | $ 20,566 | $ 29,972 |
BMRN Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 | [1] | ||||
|---|---|---|---|---|---|---|---|
| Current assets: | |||||||
| Cash and cash equivalents | $ 694,381 | $ 724,531 | |||||
| Short-term investments | 476,577 | 567,006 | |||||
| Accounts receivable, net | 610,222 | 461,316 | |||||
| Inventory | 975,546 | 894,083 | |||||
| Other current assets | 193,391 | 104,521 | |||||
| Total current assets | 2,950,117 | 2,751,457 | |||||
| Noncurrent assets: | |||||||
| Long-term investments | 385,777 | 333,835 | |||||
| Property, plant and equipment, net | 1,067,278 | 1,073,366 | |||||
| Intangible assets, net | 310,343 | 338,569 | |||||
| Goodwill | 196,199 | 196,199 | |||||
| Deferred tax assets | 1,509,290 | 1,505,412 | |||||
| Other assets | 144,168 | 176,236 | |||||
| Total assets | 6,563,172 | 6,375,074 | |||||
| Current liabilities: | |||||||
| Accounts payable and accrued liabilities | 597,231 | 572,959 | |||||
| Short-term contingent consideration | 0 | 15,925 | |||||
| Total current liabilities | 597,231 | 588,884 | |||||
| Noncurrent liabilities: | |||||||
| Long-term convertible debt, net | 1,084,994 | 1,083,019 | |||||
| Other long-term liabilities | 98,120 | 100,015 | |||||
| Total liabilities | 1,780,345 | 1,771,918 | |||||
| Stockholders’ equity: | |||||||
| Common stock, $0.001 par value: 500,000,000 shares authorized; 188,151,695 and 186,250,719 shares issued and outstanding, respectively | 188 | 186 | |||||
| Additional paid-in capital | 5,493,956 | 5,404,895 | |||||
| Company common stock held by the Nonqualified Deferred Compensation Plan | (10,393) | (8,859) | |||||
| Accumulated other comprehensive loss | (18,617) | (3,867) | |||||
| Accumulated deficit | (682,307) | (789,199) | |||||
| Total stockholders’ equity | 4,782,827 | 4,603,156 | [2] | ||||
| Total liabilities and stockholders’ equity | $ 6,563,172 | $ 6,375,074 | |||||
| |||||||
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.